新辅助化疗后前哨淋巴结活检阴性省略腋窝清扫的淋巴结复发率
该单中心队列研究纳入610例临床N1期乳腺癌患者,新辅助化疗后555例转为cN0并接受前哨淋巴结活检,其中234例检出≥3枚阴性前哨淋巴结而仅行前哨淋巴结活检、省略腋窝淋巴结清扫。中位随访40个月,仅1例发生腋窝淋巴结复发(同步局部复发,且拒绝放疗),接受放疗的205例中无淋巴结复发。
要点
- cN1乳腺癌新辅助化疗转cN0后,≥3枚前哨淋巴结阴性可安全省略腋窝清扫。
- 中位随访40个月腋窝淋巴结复发率低,仅1例且拒绝放疗。
- 接受放疗的患者中无淋巴结复发,未常规进行转移淋巴结标记。
核心结论
- cN1乳腺癌经新辅助化疗转为cN0且≥3枚前哨淋巴结阴性时,仅行前哨淋巴结活检的淋巴结复发率低,未常规行淋巴结标记,结果可能支持此类患者省略腋窝淋巴结清扫。
主要发现
- 610例中555例(91%)转为cN0并接受前哨淋巴结活检,234例(42%)检出≥3枚阴性前哨淋巴结而仅行前哨淋巴结活检。
- 234例患者中位年龄49岁(IQR 40-58),中位肿瘤大小3 cm,144例(62%)为ERBB2阳性,43例(18%)为三阴性。
- 212例(91%)接受含多柔比星的新辅助化疗,205例(88%)接受辅助放疗,其中164例(70%)同时接受淋巴结放疗。
- 中位随访40个月,仅1例腋窝淋巴结复发,与局部复发同步,该患者拒绝放疗;接受放疗的205例中无淋巴结复发。
临床怎么用
- cN1乳腺癌新辅助化疗后转为cN0,采用双示踪剂定位且检出≥3枚前哨淋巴结均病理阴性时,可考虑省略腋窝淋巴结清扫。
- 此类患者接受辅助放疗(包括淋巴结放疗)与极低淋巴结复发相关。
- 未常规标记转移淋巴结或定位标记淋巴结,此简化流程下仍观察到低复发率。
局限性
- 单中心回顾性队列设计,样本来自单一三级癌症中心。
- 中位随访40个月,缺乏长期随访数据。
- 未常规标记转移淋巴结,未评估标记淋巴结定位对复发的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prospective trials have demonstrated sentinel lymph node (SLN) false-negative rates of less than 10% when 3 or more SLNs are retrieved in patients with clinically node-positive breast cancer rendered clinically node-negative with neoadjuvant chemotherapy (NAC). However, rates of nodal recurrence in such patients treated with SLN biopsy (SLNB) alone are unknown because axillary lymph node dissection (ALND) was performed in all patients, limiting adoption of this approach. OBJECTIVE: To evaluate nodal recurrence rates in a consecutive cohort of patients with clinically node-positive (cN1) breast cancer receiving NAC, followed by a negative SLNB using a standardized technique, and no further axillary surgery. DESIGN, SETTING, AND PARTICIPANTS: From November 2013 to February 2019, a cohort of consecutively identified patients with cT1 to cT3 biopsy-proven N1 breast cancer rendered cN0 by NAC underwent SLNB with dual tracer mapping and omission of ALND if 3 or more SLNs were identified and all were pathologically negative. Metastatic nodes were not routinely clipped, and localization of clipped nodes was not performed. The study was performed in a single tertiary cancer center. INTERVENTION: Omission of ALND in patients with cN1 breast cancer after NAC if 3 or more SLNs were pathologically negative. MAIN OUTCOME AND MEASURES: The primary outcome was the rate of nodal recurrence among patients with cN1 breast cancer treated with SLNB alone after NAC. RESULTS: Of 610 patients with cN1 breast cancer treated with NAC, 555 (91%) converted to cN0 and underwent SLNB; 234 (42%) had 3 or more negative SLNs and had SLNB alone. The median (IQR) age of these 234 patients was 49 (40-58) years; median tumor size was 3 cm; 144 (62%) were ERBB2 (formerly HER2)-positive, and 43 (18%) were triple negative. Most (212 [91%]) received doxorubicin-based NAC; 205 (88%) received adjuvant radiotherapy (RT), and 164 (70%) also received nodal RT. At a median follow-up of 40 months, there was 1 axillary nodal recurrence synchronous with local recurrence in a patient who refused RT. Among patients who received RT (n = 205), there were no nodal recurrences. CONCLUSIONS AND RELEVANCE: This cohort study found that in patients with cN1 disease rendered cN0 with NAC, with 3 or more negative SLNs with SLNB alone, nodal recurrence rates were low, without routine nodal clipping. These findings potentially support omitting ALND in such patients.
引用
- Barrio AV, Montagna G, Mamtani A, et al. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event. JAMA Oncol. 2021. PMID: 34617979. doi:10.1001/jamaoncol.2021.4394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。